MICHAELA LIEDTKE

Summary

Affiliation: Stanford University
Country: USA

Publications

  1. pmc Lenalidomide, melphalan and dexamethasone in a population of patients with immunoglobulin light chain amyloidosis with high rates of advanced cardiac involvement
    Shira Dinner
    Haematologica 98:1593-9. 2013
  2. pmc The transcription factor encyclopedia
    Dimas Yusuf
    Department of Medical Genetics, Faculty of Medicine, Centre for Molecular Medicine and Therapeutics, Child and Family Research Institute, University of British Columbia, Vancouver, Canada
    Genome Biol 13:R24. 2012
  3. pmc Therapeutic targeting of MLL
    MICHAELA LIEDTKE
    Department of Pathology, Stanford University School of Medicine, Stanford, CA 94305, USA
    Blood 113:6061-8. 2009
  4. pmc Phase I trial of a novel human monoclonal antibody mAb216 in patients with relapsed or refractory B-cell acute lymphoblastic leukemia
    MICHAELA LIEDTKE
    Department of Medicine, Stanford University School of Medicine, 875 Blake Wilbur Drive, Stanford, CA 94305, USA
    Haematologica 97:30-7. 2012
  5. doi request reprint The prognostic value of diagnosing concurrent multiple myeloma in immunoglobulin light chain amyloidosis
    Shira Dinner
    Division of Hematology, Stanford University School of Medicine, Stanford, CA 94305, USA
    Br J Haematol 161:367-72. 2013
  6. pmc Sequential azacitidine plus lenalidomide combination for elderly patients with untreated acute myeloid leukemia
    Daniel A Pollyea
    Department of Medicine, Stanford University School of Medicine, Stanford, CA, USA
    Haematologica 98:591-6. 2013
  7. doi request reprint Heart transplantation and cardiac amyloidosis: approach to screening and novel management strategies
    Brandon C Varr
    Department of Internal Medicine, Stanford University School of Medicine, Stanford, CA, USA
    J Heart Lung Transplant 31:325-31. 2012
  8. ncbi request reprint A single-center experience of the nationwide daunorubicin shortage: substitution with doxorubicin in adult acute lymphoblastic leukemia
    Samit Patel
    Department of Pharmacy, Stanford Hospital, Stanford University Medical Center, Stanford, CA, USA
    Leuk Lymphoma 54:2231-5. 2013
  9. doi request reprint Plasma cell leukemia: concepts and management
    MICHAELA LIEDTKE
    Department of Medicine, Division of Hematology, Stanford Cancer Center, 875 Blake Wilbur Drive, Room 2329, Stanford, CA 94305 5821, USA
    Expert Rev Hematol 3:543-9. 2010
  10. doi request reprint Second-line mitoxantrone, etoposide, and cytarabine for acute myeloid leukemia: a single-center experience
    Holbrook E Kohrt
    Department of Medicine, Division of Hematology, Stanford University, Stanford, CA 94305, USA
    Am J Hematol 85:877-81. 2010

Research Grants

Collaborators

  • Bruno C Medeiros
  • Sally Arai
  • Daniel A Pollyea
  • JASON R GOTLIB
  • Ash A Alizadeh
  • Holbrook E Kohrt
  • Tim C P Somervaille
  • Ronald M Witteles
  • Omar Abdel-Wahab
  • Marcia M Bieber
  • Tracy I George
  • Shira Dinner
  • Stanley L Schrier
  • Samit Patel
  • Richard Lafayette
  • Wesley Witteles
  • Dimas Yusuf
  • Brandon C Varr
  • Anosheh Afghahi
  • Dat Ngo
  • Anthony Lam
  • Kelly L Prince
  • Roland H Wenger
  • Magdalena I Swanson
  • Jerzy Ostrowski
  • Gieri Camenisch
  • Jarrod Bailey
  • Jonathan S Lim
  • Bruce E Torbett
  • Peter John Noy
  • Miranda S C Wilson
  • Satrajit Sinha
  • Magdalena Karolczak-Bayatti
  • Mark W Woodcroft
  • Richard M Gronostajski
  • Scott Ferrell
  • Mariastella Zannini
  • Philip J Brown
  • Henriette O'Geen
  • Capucine Van Rechem
  • Raquel Marco-Ferreres
  • Oliver Hankinson
  • Paola Bovolenta
  • Rumela Chakrabarti
  • Bianca Blom
  • Scott A Waldman
  • Christopher J Harvey
  • Chunyan Zhao
  • Xin M Luo
  • Rachel D Mullen
  • Dominique Leprince
  • Sekhar P Reddy
  • Frances M Sladek
  • Robert F Hevner
  • Reiner A Veitia
  • David Laperriere
  • Oscar H P Ramos
  • Juan Hou
  • Daniel J Peet
  • Peggy J Farnham
  • Alison H Banham
  • Padma Sheela Jayaraman
  • Venu Raman
  • Margaret R Hough
  • Michael Wegner
  • Ralf Kist
  • Marrit Putker
  • Richard A Lafayette
  • John B Hogenesch
  • Leonardo L Beccari
  • Carol F Webb
  • Pamela A Hoodless
  • Edwin Chen
  • Luis del Peso
  • M Michela Mancarelli
  • Elizabeth Wederell
  • Seth Frietze
  • Amy Ticoll
  • Christophe Heligon
  • Michael Taggart
  • Astrid Eijkelenboom
  • Karin Dahlman-Wright
  • Christopher T D Dickman
  • Marissa Cathleen Blank
  • Lars Grontved
  • Stephanie C Colvin
  • Gerhart U Ryffel
  • Matthew E Witek
  • Yunfu Sun
  • Tiziana De Cristofaro

Detail Information

Publications11

  1. pmc Lenalidomide, melphalan and dexamethasone in a population of patients with immunoglobulin light chain amyloidosis with high rates of advanced cardiac involvement
    Shira Dinner
    Haematologica 98:1593-9. 2013
    ..Our data highlight the importance of developing novel treatment approaches for amyloid cardiomyopathy. This trial was registered at www.clinicaltrials.gov (NCT00890552). ..
  2. pmc The transcription factor encyclopedia
    Dimas Yusuf
    Department of Medical Genetics, Faculty of Medicine, Centre for Molecular Medicine and Therapeutics, Child and Family Research Institute, University of British Columbia, Vancouver, Canada
    Genome Biol 13:R24. 2012
    ..TFe aims to rapidly educate scientists about the TFs they encounter through the delivery of succinct summaries written and vetted by experts in the field. TFe is available at http://www.cisreg.ca/tfe...
  3. pmc Therapeutic targeting of MLL
    MICHAELA LIEDTKE
    Department of Pathology, Stanford University School of Medicine, Stanford, CA 94305, USA
    Blood 113:6061-8. 2009
    ..These advances in our understanding of MLL-related leukemogenesis provide a foundation for ongoing and future efforts to develop novel therapeutic strategies that will hopefully result in better treatment outcomes...
  4. pmc Phase I trial of a novel human monoclonal antibody mAb216 in patients with relapsed or refractory B-cell acute lymphoblastic leukemia
    MICHAELA LIEDTKE
    Department of Medicine, Stanford University School of Medicine, 875 Blake Wilbur Drive, Stanford, CA 94305, USA
    Haematologica 97:30-7. 2012
    ....
  5. doi request reprint The prognostic value of diagnosing concurrent multiple myeloma in immunoglobulin light chain amyloidosis
    Shira Dinner
    Division of Hematology, Stanford University School of Medicine, Stanford, CA 94305, USA
    Br J Haematol 161:367-72. 2013
    ..Evaluation of bone marrow plasma cell infiltration and presence of myeloma associated end organ damage could be clinically useful for prognostication of patients with AL...
  6. pmc Sequential azacitidine plus lenalidomide combination for elderly patients with untreated acute myeloid leukemia
    Daniel A Pollyea
    Department of Medicine, Stanford University School of Medicine, Stanford, CA, USA
    Haematologica 98:591-6. 2013
    ..In conclusion, a sequential combination of azacitidine plus lenalidomide has clinical activity in older patients with acute myeloid leukemia, and further studies of this combination are underway...
  7. doi request reprint Heart transplantation and cardiac amyloidosis: approach to screening and novel management strategies
    Brandon C Varr
    Department of Internal Medicine, Stanford University School of Medicine, Stanford, CA, USA
    J Heart Lung Transplant 31:325-31. 2012
    ..A novel strategy of OHT, followed by light-chain suppressive chemotherapy before autologous hematopoietic stem cell transplant, is feasible for patients with light-chain amyloidosis...
  8. ncbi request reprint A single-center experience of the nationwide daunorubicin shortage: substitution with doxorubicin in adult acute lymphoblastic leukemia
    Samit Patel
    Department of Pharmacy, Stanford Hospital, Stanford University Medical Center, Stanford, CA, USA
    Leuk Lymphoma 54:2231-5. 2013
    ..Higher induction mortality observed with doxorubicin substitution in this analysis needs further study...
  9. doi request reprint Plasma cell leukemia: concepts and management
    MICHAELA LIEDTKE
    Department of Medicine, Division of Hematology, Stanford Cancer Center, 875 Blake Wilbur Drive, Room 2329, Stanford, CA 94305 5821, USA
    Expert Rev Hematol 3:543-9. 2010
    ....
  10. doi request reprint Second-line mitoxantrone, etoposide, and cytarabine for acute myeloid leukemia: a single-center experience
    Holbrook E Kohrt
    Department of Medicine, Division of Hematology, Stanford University, Stanford, CA 94305, USA
    Am J Hematol 85:877-81. 2010
    ..3 and 7.6 months, P = 0.36). Despite risk stratification by the European Prognostic Index, our series demonstrates inferior rates of response and survival, illustrating the limited activity of this regimen in our cohort...
  11. pmc Self-association mediated by the Ras association 1 domain of AF6 activates the oncogenic potential of MLL-AF6
    MICHAELA LIEDTKE
    Department of Pathology, Stanford University School of Medicine, 300 Pasteur Drive, Stanford, CA 94305, USA
    Blood 116:63-70. 2010
    ..Rather, the AF6 RA1 domain efficiently mediated self-association, suggesting that constitutive MLL self-association is a more common pathogenic mechanism for MLL oncogenesis than indicated by previous studies of rare MLL fusion partners...

Research Grants2

  1. Deregulation of Ras Signaling in MLL-Induced Leukemia
    MICHAELA LIEDTKE; Fiscal Year: 2007
    ..These studies will lead to a better understanding of the molecular mechanisms of leukemogenesis mediated by a subset of MLL fusion proteins and may facilitate the development and testing of novel targeted therapies. ..